Spots Global Cancer Trial Database for stage iii grade 1 follicular lymphoma
Every month we try and update this database with for stage iii grade 1 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Beta Alethine in Treating Patients With Low-Grade Lymphoma | NCT00007839 | Lymphoma | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | NCT00017381 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac... | rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma | NCT00020462 | Lymphoma | aldesleukin autologous tumo... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | NCT01190449 | Lymphoma | ofatumumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma | NCT00006039 | Lymphoma Small Intestine... | pegylated inter... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | NCT00428142 | Lymphoma | rituximab bortezomib cyclophosphamid... prednisone vincristine sul... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma | NCT00278161 | Leukemia Lymphoma | Pegfilgrastim Rituximab Cyclophosphamid... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | NCT00118170 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | sorafenib tosyl... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone | NCT00933127 | Lymphoma | DNA analysis polymerase chai... polymorphism an... laboratory biom... | 18 Years - | SWOG Cancer Research Network | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | NCT00110149 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma | NCT00310167 | Lymphoma | radiation thera... | 18 Years - | University College, London | |
| Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab | NCT01150643 | Lymphoma | gene expression... microarray anal... polymerase chai... polymorphism an... immunohistochem... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma | NCT00784927 | Lymphoma | rituximab cyclophosphamid... dexamethasone lenalidomide | 18 Years - 120 Years | Mayo Clinic | |
| Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | NCT00003356 | Lymphoma | aldesleukin rituximab | 18 Years - 75 Years | University of Rochester | |
| Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | NCT00005626 | Leukemia Lymphoma | Irinotecan | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00004179 | Lymphoma | rituximab CHOP regimen cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma | NCT01307605 | Lymphoma | Rituximab lenalidomide | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | NCT00248430 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... | aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | NCT00118170 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | sorafenib tosyl... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402 | NCT01406782 | Lymphoma | rituximab DNA analysis gene expression... polymerase chai... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | NCT01045928 | Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac... | lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL | NCT00732498 | Lymphoma | Methylprednisol... Etoposide Cytarabine Cisplatin Rituximab In-Zevalin Y-Zevalin | 18 Years - | University of Arizona | |
| UCN-01 in Treating Patients With Advanced Cancer | NCT00003289 | Leukemia Lymphoma Unspecified Adu... | 7-hydroxystauro... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | NCT00010192 | B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... | rituximab aldesleukin laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma | NCT00117975 | Lymphoma | galiximab rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma | NCT00003204 | Stage III Grade... Stage III Grade... Stage III Grade... Stage III Small... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Small ... | cyclophosphamid... fludarabine pho... vincristine sul... prednisone rituximab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma | NCT00006252 | Leukemia Lymphoma | fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt... | - 69 Years | Alliance for Clinical Trials in Oncology | |
| Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab | NCT01150643 | Lymphoma | gene expression... microarray anal... polymerase chai... polymorphism an... immunohistochem... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma | NCT00258336 | Lymphoma | autologous immu... rituximab sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00006721 | Lymphoma | rituximab cyclophosphamid... doxorubicin prednisone vincristine tositumomab | 18 Years - | SWOG Cancer Research Network | |
| Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | NCT00551239 | Leukemia Lymphoma | rituximab fludarabine pho... pixantrone dima... | 18 Years - 120 Years | CTI BioPharma | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma | NCT00896519 | Lymphoma | rituximab sargramostim cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... gene expression... gene rearrangem... polymerase chai... R-CHOP regimen laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | NCT00003639 | Lymphoma | recombinant int... chlorambucil dexamethasone idarubicin | 15 Years - 70 Years | National Cancer Institute (NCI) | |
| Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma | NCT00553501 | Lymphoma | epratuzumab rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | NCT00003152 | Lymphoma | filgrastim recombinant int... cyclophosphamid... prednisone vincristine sul... autologous bone... bone marrow abl... peripheral bloo... radiation thera... | 18 Years - 65 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | NCT00411086 | Lymphoma | Rituximab Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma | NCT00089115 | Lymphoma | autologous immu... rituximab sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma | NCT00004198 | Lymphoma | keyhole limpet ... sargramostim tumor cell-base... | 18 Years - 120 Years | University of Nebraska | |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | NCT00275080 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Secondary Acute... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Untreated Adult... Untreated Adult... | vorinostat decitabine | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma | NCT00003605 | Lymphoma | rituximab cyclophosphamid... | - | Hoag Memorial Hospital Presbyterian | |
| Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00387959 | Leukemia Lymphoma | filgrastim rituximab cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... umbilical cord ... total-body irra... | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| UCN-01 in Treating Patients With Advanced Cancer | NCT00003289 | Leukemia Lymphoma Unspecified Adu... | 7-hydroxystauro... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00006721 | Lymphoma | rituximab cyclophosphamid... doxorubicin prednisone vincristine tositumomab | 18 Years - | SWOG Cancer Research Network | |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | NCT00004084 | Leukemia Lymphoma | indium In 111 L... yttrium Y 90 ep... | 18 Years - | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | |
| Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | NCT00301795 | Stage III Grade... Stage III Grade... Stage III Grade... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... | oblimersen sodi... rituximab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00003849 | Lymphoma | rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma | NCT00553501 | Lymphoma | epratuzumab rituximab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | NCT00026351 | Leukemia Lymphoma | rituximab pentostatin | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | NCT00110149 | Lymphoma | rituximab yttrium Y 90 ib... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma | NCT00411086 | Lymphoma | Rituximab Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma | NCT00028691 | Lymphoma | chlorambucil radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00003784 | Lymphoma | CHOP regimen cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... tositumomab and... | 18 Years - | SWOG Cancer Research Network | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma | NCT00893477 | Lymphoma | rituximab sargramostim gene expression... gene rearrangem... polymerase chai... polymorphism an... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | NCT00003338 | Lymphoma | immunoscintigra... technetium Tc 9... | 16 Years - 120 Years | Gilead Sciences | |
| Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma | NCT00006039 | Lymphoma Small Intestine... | pegylated inter... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911 | NCT00896922 | Lymphoma | microarray anal... immunohistochem... laboratory biom... | 16 Years - 120 Years | SWOG Cancer Research Network | |
| Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma | NCT00637832 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisolone vincristine sul... yttrium Y 90 ib... | 18 Years - 120 Years | University of Southampton | |
| Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | NCT00017381 | Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac... | rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma | NCT00028665 | Lymphoma | filgrastim rituximab carmustine cisplatin cyclophosphamid... etoposide bone marrow abl... peripheral bloo... radiation thera... | 12 Years - 65 Years | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
